American Association for Cancer Research Annual Meeting (AACR)

Articles

Alessi detailed his research into cancer aneuploidy and its predictive capabilities for treating patients with non–small cell lung cancer.

João Alessi, MD, on the Ability for Cancer Aneuploidy to Predict Immunotherapy Response in NSCLC

Videos

CancerNetwork® spoke with Sanju Sinha of the National Cancer Institute about the resulting data from his research into sex differences associated with using tumor mutational burden to predict response to PD-1 inhibition.

NCI Investigator on the Results of a Study Exploring Sex Bias Related to TMB as a Biomarker of PD-1 Inhibitors

Holowatyj touched on the need to learn more about the biological factors contributing to disparities in early-onset colorectal cancer and the associated burden of the disease.

Andreana N. Holowatyj, PhD, MS, Discusses Focal Questions Regarding Colorectal Cancer Disparities

CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how results of a study aimed at determining pathological complete response in patients with locally advanced breast cancer by cell-free DNA may spare certain patients from needing further biopsies. 

Francesco Ravera, MD, PhD, on How cfDNA for pCR Assessment May Spare Biopsies in Breast Cancer

CancerNetwork® spoke with Neelam and Sanju Sinha of the National Cancer Institute about their research into sex differences associated with using tumor mutational burden to predict response to PD-1 inhibition. 

Investigators on the Rationale for Exploring Sex Bias Related to TMB as a Biomarker of PD-1 Inhibitors

CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss results of a study aimed at determining pathological complete response in patients with locally advanced breast cancer by either cell-free DNA assessment or traditional MRI. 

Francesco Ravera, MD, PhD, on Results of cfDNA Versus MRI to Predict pCR After Neoadjuvant Therapy in Breast Cancer

CancerNetwork® spoke with Francesco Ravera, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 to discuss a study that looked at cell-free DNA assessment compared with traditional MRI for determining pathological complete response in patients with locally advanced breast cancer. 

Francesco Ravera, MD, PhD, on the Rationale for Comparing cfDNA to MRI for Predicting pCR After Neoadjuvant Therapy in Breast Cancer

Kim discussed the need for further CREB inhibitor combinations to target collateral pathways and improve patient outcomes.

Michael Kim, MD, on Developing More CREB Inhibitors in Pancreatic Cancer Moving Forward

Low-grade, manageable treatment-emergent adverse effects and low rates of discontinuation were associated with the RET inhibitor selpercatinib as therapy for patients with RET-altered advanced solid tumors who were treated on the LIBRETTO-001 trial.


Post-Hoc Analysis of Pivotal Trial Demonstrates Safety of Selpercatinib in RET-Altered Advanced Solid Tumors

The lymphoma expert discussed how adding copanlisib to rituximab improved progression-free survival, while demonstrating a manageable safety profile in patients with relapsed indolent non-Hodgkin lymphoma.

American Association for Cancer Research Annual Meeting (AACR) | Conference